XOMA Corp. Stock
Price
Target price
€36.60
€36.60
0.560%
0.2
0.560%
€38.50
04.06.26 / Tradegate
WKN: A2ATUH / Symbol: XOMA / Name: XOMA / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
XOMA Corp. Stock
XOMA Corp. gained 0.560% compared to yesterday.
XOMA Corp. is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
As a result the target price of 38 € shows a slightly positive potential of 3.83% compared to the current price of 36.6 € for XOMA Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for XOMA Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of XOMA Corp. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of XOMA Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| XOMA Corp. | 0.560% | 2.235% | 3.977% | 72.642% | 69.444% | 125.926% | 51.240% |
| Heron Therapeutics Inc. | 7.600% | -44.735% | -62.112% | -78.738% | -64.901% | -64.455% | -96.604% |
| Evolus Inc | -2.000% | 1.124% | 4.223% | -32.388% | 2.349% | -29.392% | -36.614% |
| Rhythm Pharmaceuticals | -1.330% | -1.333% | -7.500% | 29.825% | -20.856% | 356.790% | 380.519% |
Comments
XOMA Royalty (NASDAQ:XOMA) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Show more
Ratings data for XOMA provided by MarketBeat
XOMA Royalty (NASDAQ:XOMA) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Show more
Ratings data for XOMA provided by MarketBeat
XOMA Royalty (NASDAQ:XOMA) was given a new $45.00 price target on by analysts at Leerink Partners. They now have an "outperform" rating on the stock.
Show more
Ratings data for XOMA provided by MarketBeat
News
Ligand Pharmaceuticals Q1 Earnings Call Highlights
Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties
